{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-23-000018","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.191055+00:00","generated_at":"2026-06-08T16:26:55.555158+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arcus Biosciences Q3 net loss $71M; cash $950M; domvanalimab and AB521 updates","bullets":["Net loss of $71M in Q3 2023 vs $65M in Q3 2022; R&D expenses rose to $82M from $77M.","Cash, cash equivalents and marketable securities $950M as of Sept 30, 2023, down from $1.1B at Dec 31, 2022; cash runway into 2026.","Revenue $32M in Q3 2023, primarily from Gilead collaboration, vs $33M in Q3 2022.","EDGE-Gastric Phase 2: domvanalimab + zimberelimab + chemo showed 80% ORR in PD-L1-high tumors; maturity PFS data expected H2 2024.","AB521 Phase 1/1b: PK/PD consistent with healthy volunteers; no DLTs; ccRCC dose-expansion near completion; efficacy data later in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-23-000018","json":"https://secwatch.observer/filing/0001724521-23-000018.json","markdown":"https://secwatch.observer/filing/0001724521-23-000018.md","text":"https://secwatch.observer/filing/0001724521-23-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452123000018/0001724521-23-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452123000018/rcus-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:26:55.555158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3fd640e347293e787c75f66469145dccfb016265","claim":"Arcus Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023 , Arcus Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452123000018/0001724521-23-000018-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}